You are here: Industry Insights > RedHill Biopharma

News List

RedHill Biopharma Reports that Opaganib Mechanism Not Impacted by Viral Spike-Protein Mutations, Including Omicron Mutations prnasia
December 07, 2021
Opaganib works by targeting the human host cell rather than the virus itself and is therefore not expected to be impacted by spike protein mutations, providing a strong rationale for its potential to address the Omicron...
RedHill Biopharma reports rise in Q3 2021 net revenues Pharmaceutical-Technology
December 02, 2021
RedHill Biopharma has reported net revenues of $21.6m in the third quarter (Q3) of this year, representing an increase from $21.5m in the second quarter of the year.
RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients prnewswire
November 16, 2021
RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the last patient has been enrolled in Part A of the Phase 2/3 study with novel...
RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients prnewswire
September 23, 2021
While preliminary top-line data of the study efficacy endpoints showed consistent trends in favor of the opaganib arm, the study endpoints did not achieve statistical significance
RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant prnewswire
August 27, 2021
RedHill Biopharma Ltd. today announced preliminary results of a new preclinical study showing strong inhibition by opaganib (ABC294640)[1] of Delta variant replication while maintaining cell viability at relevant concentrations.
RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib prnewswire
July 20, 2021
RedHill Biopharma Ltd. today announced that all treatment and follow-up has now been completed in the 475-patient global Phase 2/3 study with opaganib (ABC294640)[1] in patients hospitalized with severe COVID-19 pneumonia (NCT04467840).
RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study prnasia
June 29, 2021
RedHill announced preliminary results of a new preclinical study showing potent inhibition of COVID-19 variants of concern by opaganib (Yeliva®, ABC294640)[1].
RedHill Biopharma Announces Presentation of Positive Oral Opaganib Phase 2 Data in COVID-19 prnasia
June 22, 2021
RedHill Biopharma Ltd. announced presentation of the positive Phase 2 safety and efficacy data for oral opaganib (Yeliva®, ABC294640)[1] in hospitalized patients with COVID-19 pneumonia at the World Microbe Forum (WMF) 2021.
RedHill Biopharma Completes Enrollment of Oral Opaganib Phase 2/3 COVID-19 Study prnasia
June 08, 2021
RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that it has completed enrollment and randomized the last patient in the global Phase 2/3 study with opaganib (Yeliva®, ABC294640)[1] in patients hospitalized with severe ...
RedHill Biopharma Receives Allowances for U.S. Patent Applications Covering Opaganib and RHB-107 for COVID-19 prnasia
May 27, 2021
RedHill Biopharma Ltd. announced receipt of two Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) covering opaganib[1] and RHB-107 (upamostat)[2] as methods for the treatment of COVID-19 caused by the SARS-CoV-2 virus.